Pharmacokinetics, Bioavailability, and Tissue Distribution of Magnolol Following Single and Repeated Dosing of Magnolol to Rats

Abstract

Magnolol (M) is a polyphenol antioxidant abundant in the bark of Magnolia officinalis Rehder & E. Wilson, a popular Chinese herb. To understand the pharmacokinetics and bioavailability of M, Sprague-Dawley rats were intravenously injected with a bolus of M (20 mg/kg) and orally given a single dose and seven doses of M (50 mg/kg). Blood samples were withdrawn via cardiopuncture at specific times. Organs including the liver, kidney, brain, lung, and heart were collected at 30 min after the 7th oral dose. The serum and tissue specimens were assayed by HPLC before and after hydrolysis with β-glucuronidase and sulfatase. The results showed that after intravenous bolus, the systemic exposure of magnolol glucuronides (MG) was comparable with that of M while after oral administration, magnolol sulfates/glucuronides (M S/G) were predominant in the bloodstream. Conversely, M was predominant in the liver, kidney, brain, lung, and heart. Among the studied organs, the liver contained the highest concentrations of M and MG. In conclusion, M S/G was the major form in circulation, whereas M was predominant in the liver, kidney, brain, lung, and heart after oral administration of M; among these organs, the liver contained the highest concentrations of M and MG.

Key words

magnolol - sulfates/glucuronides - pharmacokinetics - tissue distribution - HPLC - Magnolia officinalis - Magnoliaceae

References

• 1 Chen Q S. Houpo. In: Chang H M, But P P H, editors Pharmacology and applications of Chinese materia medica. Singapore: World Scientific; 1986: 878-880
• 2 Wang J P, Hsu M F, Raung S L, Chang L C, Tsao L T, Lin P L, Chen C C. Inhibition by magnolol of formylmethionyl-leucyl-phenyl alanine-induced respiratory burst in rat neutrophils.  J Pharm Pharmacol. 1999;  51 285-294
• 3 Lin Y R, Chen H H, Ko C H, Chan M H. Effects of honokiol and magnolol on acute and inflammatory pain models in mice.  Life Sci. 2007;  81 1071-1078
• 4 Lee J, Jung E, Park J, Jung K, Lee S, Hong S, Park J, Park E, Kim J, Park S, Park D. Anti-inflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-kappaB activation signaling.  Planta Med. 2005;  71 338-343
• 5 Park J, Lee J, Jung E, Park Y, Kim K, Park B, Jung K, Park E, Kim J, Park D. In vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium sp.  Eur J Pharmacol. 2004;  496 189-195
• 6 Lin S Y, Chang Y T, Liu J D, Yu C H, Ho Y S, Lee Y H, Lee W S. Molecular mechanisms of apoptosis induced by magnolol in colon and liver cancer cells.  Mol Carcinogen. 2001;  32 73-83
• 7 Nagase H, Ikeda K, Sakai Y. Inhibitory effect of magnolol and honokiol from Magnolia obovata on human fibrosarcoma HT-1080. Invasiveness in vitro.  Planta Med. 2001;  67 705-708
• 8 Lin S Y, Liu J D, Chang H C, Yeh S D, Lin C H, Lee W S. Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis.  J Cell Biochem. 2002;  84 532-544
• 9 Ikeda K, Nagase H. Magnolol has the ability to induce apoptosis in tumor cells.  Biol Pharm Bull. 2002;  25 1546-1549
• 10 Chang B, Lee Y, Ku Y, Bae K, Chung C. Antimicrobial activity of magnolol and honokiol against periodontopathic microorganisms.  Planta Med. 1998;  64 367-369
• 11 Ho K Y, Tsai C C, Chen C P, Huang J S, Lin C C. Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis.  Phytother Res. 2001;  15 139-141
• 12 Chan S S, Zhao M, Lao L, Fong H H, Che C T. Magnolol and honokiol account for the anti-spasmodic effect of Magnolia officinalis in isolated guinea pig ileum.  Planta Med. 2008;  74 381-384
• 13 Nakazawa T, Yasuda T, Ohsawa K. Metabolites of orally administered Magnolia officinalis extract in rats and man and its antidepressant-like effects in mice.  J Pharm Pharmacol. 2003;  55 1583-1591
• 14 Watanabe K, Watanabe H, Goto Y, Yamaguchi M, Yamamoto N, Hagino K. Pharmacological properties of magnolol and honokiol extracted from Magnolia officinalis: central depressant effects.  Planta Med. 1983;  49 103-108
• 15 D'Archivio M, Filesi C, Di Benedetto R, Gargiulo R, Giovannini C, Masella R. Polyphenols, dietary sources and bioavailability.  Ann Ist Super Sanita. 2007;  43 348-361
• 16 Hattori M, Endo Y, Takebe S, Gargiulo R, Giovannini C, Masella R. Metabolism of magnolol from Magnoliae cortex. II. Absorption, metabolism and excretion of [ring-¹⁴C]magnolol in rats.  Chem Pharm Bull (Tokyo). 1986;  34 158-167
• 17 Tsai T H, Chou C J, Chen C F. Pharmacokinetics and brain distribution of magnolol in the rat after intravenous bolus injection.  J Pharm Pharmacol. 1996;  48 57-59
• 18 Shipkova M, Wieland E. Glucuronidation in therapeutic drug monitoring.  Clin Chim Acta. 2005;  358 2-23
• 19 Ritter J K. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions.  Chem Biol Interact. 2000;  129 171-193
• 20 Kauffman F C. Sulfonation in pharmacology and toxicology.  Drug Metab Rev. 2004;  36 823-843
• 21 Kaminsky L S, Zhang Q Y. The small intestine as a xenobiotic-metabolizing organ.  Drug Metab Dispos. 2003;  31 1520-1525
• 22 Rice-Evans C, Spencer J P, Schroeter H, Rechner A R. Bioavailability of flavonoids and potential bioactive forms in vivo.  Drug Metabol Drug Interact. 2000;  17 291-310
• 23 Liu Z, Hu M. Natural polyphenol disposition via coupled metabolic pathways.  Expert Opin Drug Metab Toxicol. 2007;  3 389-406
• 24 Tsai T H, Chou C J, Lee T F, Wang L C H, Chen C H. Pharmacokinetic and pharmacodynamic studies of magnolol after oral administration in rats.  Pharm Sci. 1996;  2 191-193
• 25 Sperker B, Murdter T E, Schick M, Eckhardt K, Bosslet K, Kroemer H K. Interindividual variability in expression and activity of human β-glucuronidase in liver and kidney: consequences for drug metabolism.  J Pharmacol Exp Ther. 1997;  281 914-920
• 26 Hanson S R, Best M D, Wong C H. Sulfatases: structure, mechanism, biological activity, inhibition, and synthetic utility.  Angew Chem Int Ed Engl. 2004;  43 5736-5763
• 27 Coughtrie M W, Sharp S, Maxwell K, Innes N P. Biology and function of the reversible sulfation pathway catalysed by human sulfotransferases and sulfatases.  Chem Biol Interact. 1998;  109 3-27
• 28 Wittwer E, Kern S E. Role of morphine's metabolites in analgesia: concepts and controversies.  AAPS J. 2006;  8 E348-E352
• 29 Joshi G P. Morphine-6-glucuronide, an active morphine metabolite for the potential treatment of post-operative pain.  Curr Opin Investig Drugs. 2008;  9 786-799
• 30 Yang J H, Hsia T C, Kuo H M, Chao P D, Chou C C, Wei Y H, Chung J G. Inhibition of lung cancer cell growth by quercetin glucuronides via G2/M arrest and induction of apoptosis.  Drug Metab Dispos. 2006;  34 296-304
• 31 Moon J H, Tsushida T, Nakahara K, Terao J. Identification of quercetin 3-O-β-D-glucuronide as an antioxidative metabolite in rat plasma after oral administration of quercetin.  Free Radic Biol Med. 2001;  30 1274-1285
• 32 Fang S H, Hou Y C, Chang W C, Hsiu S L, Chao P D, Chiang B L. Morin sulfates/glucuronides exert anti-inflammatory activity on activated macrophages and decreased the incidence of septic shock.  Life Sci. 2003;  74 743-756
• 33 Hsieh C L, Chao P D, Fang S H. Morin sulphates/glucuronides enhance macrophage function in microgravity culture system.  Eur J Clin Invest. 2005;  35 591-596